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INTRODUCTION 
Human immunodeficiency virus (HIV) infection /Acquired Immunodeficiency 
Syndrome is a global pandemic, with cases reported from virtually every country. 
While initially limited, infection with the HIV has literally exploded over the past 
two decades to become the worst epidemic of the twentieth century. With more 
than 35 million fatalities, the AIDS epidemic now ranks alongside the influenza 
pandemic of the early 1900s and the Bubonic plague of the fourteenth century in 
terms of fatalities.[9] Unfortunately, the epidemic continues to spread relentlessly 
into new areas and to consolidate in many other locations. It is caused by a lenti 
virus human immunodeficiency virus. It was first recognized in USA in 1981 and 
the virus was first isolated in 1983. It has spread all over the world and by the end 
of 2007, 33.2 million individuals were living with HIV infection according to 
WHO- UNAIDS.[7]  
 More than 95% of people living with HIV/AIDS reside in developing countries 
mainly in African and asian continents. More than two thirds, approximately 22.5 
million people were living in sub-Saharan Africa. In Asia, an estimated 4.9 million 
people were living with HIV at the end of 2007 of which 2.4 million people were 
living in India alone.  
Highly Active Anti Retroviral Therapy is a novel treatment available since 1996, 
and has dramatically changed the evolution of HIV infection, with marked 
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improvement in survival and quality of life in developed countries where it was 
initially used. As a result, the gap between outcomes for HIV-infected persons in 
the rich developed world and the poor developing world began to widen. The need 
to close the treatment gap was declared a global public health emergency by WHO 
in 2003. The "3 by 5" initiative, launched by UNAIDS and WHO in December 
2003, was a global strategy to provide antiretroviral therapy to people in 
developing countries. From then on HAART became available in resource poor 
countries.     
HIV infection was first detected in India in 1986, among female sex workers in 
Chennai. From then on infection rates soared throughout the 1990s, and today the 
epidemic affects all sectors of Indian society, not just select  groups. In 1987 a 
National AIDS Control Programme was launched to co-ordinate national 
responses. In 1992 the government set up NACO (National AIDS Control 
Organisation), to oversee the formulation of policies, prevention work and control 
programmes relating to HIV and AIDS. NACO launched the Highly Active Anti 
Retroviral Therapy (HAART), in the form of fixed drug combinations on April 
2004, and was available in eight government hospitals through out the country,  
including Chennai. Though ART was available since 2004 in India, there are very 
few reports studying the efficacy of HAART, its adverse effects in our population, 
adherence of our population to therapy, and other factors.  
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ART centre was set up at our hospital in 2005, and is fully functional since then, 
catering to the needs of HIV patients. We report the outcomes of newly diagnosed, 
ART naive HIV patients started on HAART between  January 2007 to December 
2007.  
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Aims and Objectives 
 
1. To analyse the early clinical outcomes of antiretroviral-naïve adults in 
a public sector ART programme in resource limited setting. 
2. To study the trends of cd4 counts, weight, haemoglobin  with 
treatment. 
3. To determine risk factors, causes of death among patients accessing 
ART.  
4. To analyse the adverse effect profile of  ART.  
5. To analyse the trend of opportunistic infections after starting ART. 
6. To analyse the adherence to ART in public care settings. 
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REVIEW OF LITERATURE 
The acquired immunodeficiency syndrome (AIDS) was first recognized among 
homosexual men in the United States in 1981 [1]. While initially limited, infection 
with the human immunodeficiency virus (HIV) has literally exploded over the past 
two decades to become the worst epidemic of the twentieth century. 
ORIGIN OF THE HIV EPIDEMIC 
Molecular phylogenetic studies suggest that HIV evolved from simian 
immunodeficiency virus (SIV), which has been found in two of four subspecies of 
chimpanzees in the Cameroon [2]. Several lines of evidence support zoonotic 
transmission of primate lentiviruses into humans [3]. Similarities in viral genome 
between SIV and HIV, prevalence in the natural host, geographic association 
between the animal reservoir and emergence of human cases, plausible route of 
transmission. The Pan troglodytes troglodytes species of chimpanzees has been 
established as the natural reservoir of HIV-1 and the most likely source of original 
human infection. HIV-2 is more closely related phylogenetically to the simian 
immunodeficiency virus (SIV) found in sooty mangabeys than it is to HIV-1 [1]. 
HIV-1 has evolved into groups M, N, and O; M ("Main") is considered the 
pandemic strain and comprises the vast majority of strains of HIV. [3,4] Viruses 
from group M are subsequently divided into ten distinct subtypes (A to J). Group O 
("Outlier") represents far fewer strains from Cameroon, Gabon, and Equatorial 
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Guinea. Group N ("non-M/non-O") is represented by very few isolates and has 
only been documented in Cameroon. Studies have been performed to ascertain the 
origins of HIV infection. In an extensive field study, SIV-specific antibodies and 
nucleic acids were assayed in urine and fecal samples collected from the forest 
floor in the Cameroon.[5] Through sequence analysis, the origins of pandemic 
(group M) and nonpandemic (group N) HIV could be traced to distinct, 
geographically isolated chimpanzee communities. The origin of group O HIV is 
still unknown. Direct evidence of simian-to-human transmission is still missing, 
but is inferred by the known practice of hunting chimpanzees for food 
("bushmeat"), particularly in western Africa.[3] Unlike other more readily 
transmitted zoonoses, important viral adaptations may have been required for HIV 
to infect humans. These adaptations may have included the acquisition of viral 
regulatory genes such as vpu, vif, nef, and tat, and structural genes, gag and env.[2] 
Although infected chimpanzees develop high levels of viremia, they do not have 
evidence of immune activation, T cell depletion, or clinical disease.[2] However, 
SIV can cause AIDS after cross-species transmission from asymptomatic African 
sooty mangabeys  to Asian macaques.[6] 
WORLDWIDE STATISTICS  
As of December 2007, 33.2 million people were estimated to be living with 
HIV/AIDS, and more than 35 million had died since the beginning of the epidemic. 
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[7] Of the 33.2 million, 22.5 million were living in sub-Saharan Africa alone, where 
the adult prevalence rate is 5.0 percent. More than half of those living with 
HIV/AIDS are women. It is estimated that 15 million children have been orphaned 
by the premature death of both parents due to AIDS, placing enormous 
responsibilities on communities, and 2 million children are living with HIV/AIDS. 
In terms of the recent growth of the epidemic, an estimated 2.7 million people 
became newly infected with HIV in 2007, including 370 000 children under age 
15, many of whom became infected by perinatal transmission.[7] An additional 2.1 
million people died due to AIDS in 2007, including 330,000 children. Each day 
more than 6800 people become newly infected with HIV with increasing numbers 
among young adults, women, and children; and more than 5700 people die from 
AIDS each day. Young people, 15–24 years of age account for 45% of all new 
HIV infections in adults. Over 1,150 children become infected daily as a result of 
mother-to-infant transmission, despite data that antiretroviral drugs given at the 
time of delivery and to the infant after birth can largely prevent this.[8] 
Unfortunately, antiretroviral prophylaxis to prevent mother-to-child transmission 
reaches only 10 percent or less of affected mothers.[8] Of the 370 000 infants and 
children infected with HIV in year 2007, 70 percent were born in sub-Saharan 
Africa, 25 percent in southeast Asia, and the remainder in Latin America and the 
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Caribbean. With escalation of the epidemic in southeast Asia and eastern Europe, 
these numbers are only likely to increase.[7] 
Sub-Saharan Africa — Approximately 10 percent of the world population lives in 
sub-Saharan Africa, but the region is home to approximately 67 percent of the 
world population living with HIV infection.[9]All countries in this region have an 
HIV seroprevalence rate that is above 5 percent, with some as high as 25 percent.[9] 
Asia — Of the 4.5 million HIV-infected persons living in Asia, more than half live 
in India.[9] The estimates for India are based primarily on anonymous testing data 
from public clinics for prenatal care and for patients with other STDs.[9] 
Approximately 85 percent of HIV transmission in India is thought to be through 
sexual contact. In China, the government estimates that over one million people are 
infected with HIV, which represents an HIV prevalence of approximately 0.05 
percent of the general population.[11] Among new HIV infections in China, 49 
percent are caused by drug use and approximately 50 percent by sexual 
transmission. 
Americas — After sub-Saharan Africa, the Caribbean has the second highest HIV 
seroprevalence rates in the world.[9] 
Indian statistics 
The 2006 estimates suggest national adult HIV prevalence in India is 
approximately 0.36 percent, amounting to between 2 and 3.1 million people with 
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an average figure of  2.5 million people living with HIV and AIDS; almost 50 
percent of the previous estimate of 5.2 million. More men are HIV positive than 
women. Nationally, the prevalence rate for adult females is 0.29 percent, while for 
males it is 0.43 percent meaning, that for every 100 people living with HIV and 
AIDS, 61 are men and 39 women. Prevalence is also high in the 15-49 age group 
(88.7 percent of all infections), indicating that AIDS still threatens the cream of 
society, those in the prime of their working life. Adult HIV prevalence among the 
general population is 0.36 percent, among Injecting Drug Users (IDUs), it is as 
high as 8.71 percent, while it is 5.69 percent and 5.38 percent among Men who 
have Sex with Men (MSM) and Female Sex Workers (FSWs), respectively.[12] 
MODES OF TRANSMISSION AND DYNAMICS OF THE EPIDEMIC  
 The major modes of HIV infection are [13, 14] : 
    - Sexual transmission, including via heterosexual and homosexual contact 
    - Parenteral transmission: predominantly among injection drug users (IDU), 
blood transfusions 
   -  Perinatal transmission 
HIV infection is predominantly a sexually transmitted disease (STD) worldwide. 
Despite the initial description of the disease among men who have sex with men 
(MSM) in the United States, more than 80 percent of infections occur through 
heterosexual transmission, throughout the world, and over 50 percent of all HIV-
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infected people in the world are women.[15] In the United States, ~49% of the 
HIV/AIDS cases diagnosed in 2005 among adults and adolescents were attributed 
to male-to-male sexual contact. Heterosexual contact accounted for another 32%. 
The yearly incidence of new cases of AIDS attributed to heterosexual transmission 
of HIV is steadily increasing in the United States.[1] Worldwide, the most common 
mode of infection, particularly in developing countries, is clearly heterosexual 
transmission. Since the level of HIV infection is so high among women, the 
potential exists for large numbers of infected children, since infants can become 
infected with HIV in utero, at birth, or during breastfeeding. Mother-to-child 
transmission accounts for 90 percent of infection among children worldwide. In the 
worst-affected countries in the world, such as sub-Saharan Africa between 20 and 
40 percent of pregnant women are HIV-infected, and one-third of their babies are 
infected.[7] IDU is fueling epidemics in central and eastern Europe and in some 
countries of Asia. It is also a major concern in industrialized nations and the 
Middle East. Within each region, each country, and each community, the HIV 
epidemic has established its own unique character, depending upon the time of 
introduction of the virus, the social fabric of that community, its culture, its sexual 
networks, the mobility of the people and the reaction of the government to 
mounting an AIDS control program.[13] Countries in sub-Saharan Africa and the 
Caribbean currently have the highest national rates of adult HIV prevalence. 
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PATHOGENESIS AND PROGRESSION OF DISEASE 
     HIV is a member of the lentivirus family of retroviruses. HIV appears as 
spherical particles that are approximately 110 nm in diameter, with knob like 
projections on the surface of the virus and a cone-shaped viral core.[16] The genome 
is organized into three major regions (gag, pol and env ) and has six regulatory 
genes that are vital for its life cycle and pathogenicity .[17] 
LIFECYCLE 
In the lifecycle of HIV the first point of interaction consists of the binding of the 
HIV envelope surface protein gp120 with the CD4 receptor on the host cell 
assisted by co receptors, significantly CCR5 and CXCR4 expressed predominantly 
by macrophages and lymphocyte respectively, and the subsequent exposure of the 
other HIV envelope protein, gp41. 
After the fusion of the viral and cellular membranes, the viral capsid enters the cell 
and the HIV reverse transcriptase enzyme converts the single stranded HIV RNA 
into a double stranded DNA, which then is integrated with host chromosome by 
the viral enzyme integrase. Cellular enzymes transcribe the provirus into mRNA 
which is then translated into the structural proteins or which serve as genomic 
RNA for progeny virus. Viral replication involve both the assembly of the viral 
particles, with each viral core incorporating two copies of the viral RNA genome, 
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and the budding and release of the virus from the cell surface mediated by HIV 
protease enzyme. 
Disease progression 
Shortly after acute HIV infection, HIV begins to preferentially destroy HIV-
directed CD4+ helper T cells; this process impairs the critical interaction between 
host CD4+ T cells and CD8+ T cells and thus weakens the host CTL response. 
HIV extensively seeds lymphoid organs and the central nervous system. As a 
result, the infection persists, and continued rounds of replication lead to the gradual 
depletion of all CD4+ T cells. At the same time, a subset of activated, HIV-
infected CD4+ cells returns to a quiescent state, remains latently infected.[20] The 
CD4+ T cell count provides an accurate way to assess the current immunologic 
status. The plasma HIV RNA level is strong independent predictor of the 
progression to AIDS in untreated HIV-infected persons.[19] In essence, the higher 
the HIV RNA level, the more rapidly the disease will progress.      
  
CLINICAL FEATURES  
Primary infection 
Primary infection is symptomatic in 70-80% of infected individuals and usually 
occurs 2-4 weeks after exposure. The major clinical manifestations are fever (seen 
in 80% - 90%), rash (40%-80%), headache(32%-70%), lymphadenopathy (40%-
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70%), pharyngitis (50%-70%) and myalgias or arthralgias (50%-70%) .[21] Acute 
HIV illness typically persists for less than 14 days, but some patients have had 
illnesses that have extended for longer than 10 weeks. The appearance of specific 
anti-HIV antibodies in serum takes place 3-12 weeks later, although very rarely 
seroconversion may take place after 3 months. 
Asymptomatic stage - clinical latency 
The median time of this stage is about 10 years during which HIV replication is 
ongoing and progressive. The rate of disease progression is directly correlated to 
with HIV RNA levels as stated above. Long term nonprogressors show little, if 
any, decline in CD+ T cell counts. During the asymptomatic phase, the average 
rate of CD4+ Tcells decline is 50/uL per year. When the CD4+ T cell count falls 
below 200/uL, the resulting immunodeficiency leads to symptomatic disease. 
Symptomatic disease – AIDS 
     Acquired immunodeficiency syndrome (category c disease) is defined by the 
development of specified opportunistic infections, tumors etc.  
Common AIDS defining conditions – 
 Oesophageal candidiasis 
 Cryptococcal meningitis 
 Chronic cryptosporidial diarrhea 
 CMV retinitis 
23 
 
 Chronic mucocutaneous herpes simplex 
 Disseminated mycobacterium avium intercellulare 
 Miliary or extrapulmonary tuberculosis 
 Pneumocystis pneumonia 
 Cerebral toxoplasmosis 
 Kaposis’s sarcoma 
 HIV encephalopathy / PML 
 Lymphoma  
The listed AIDS defining conditions are as per revised CDC classification (1993) 
which categorizes persons on the basis of clinical conditions and CD4+ T 
lymphocyte counts.[22] For children less than 13 years of age, there is a modified 
and revised classification system for HIV infection. The WHO has also published a 
staging system for HIV infection. The WHO classification is an approach for use 
in resource limited settings and is widely used in African and Asian continents.  
WHO STAGING OF HIV INFECTION 
Clinical group – I 
   Acute HIV infection 
   PGL 
   Asymptomatic 
Normal activity 
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Clinical group – 2 (early stage disease) 
Weight loss less than 10% 
Muco cutaneous problem 
Herpes zoster 
Recurrent URI 
Normal activity 
Clinical group – 3 (intermediate disease) 
Weight loss less than 10% 
Chronic diarrhea 
Prolonged fever 1 month 
Oral candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis 
Severe bacterial infection 
Bed ridden less than 50% of day (previous month) 
DIAGNOSIS 
The diagnosis of HIV infection depends upon the demonstration of antibodies to 
HIV infection is the ELISA, also referred to as enzyme immunoassay (EIA). This 
solid – phase assay is an extremely good screening test with a sensitivity of 
>99.5%. most diagnostic laboratories use a commercial EIA kit that contains 
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antigens from both HIV-1 and -2 and thus are able to detect either. These kits use 
both natural and recombinant antigens and are continuously updated to increase 
their sensititvity to newly discovered species, such as group O viruses. EIA tests 
are generally scored as positive (highly reactive), negative (nonreactive), or 
indeterminate (partially reactive). While the EIA is an extremely sensitive test, it is 
not optimal with regard to specificity.  
The most commonly used confirmatory test is the western blot. This assay takes 
advantage of the fact that multiple HIV antigens of different, well characterized 
molecular weight elicit the production of specific antibodies. These antigens can be 
separated on the absis of molecular weight, and antibodies ot each component can 
be detected as discrete bands on the western blot.[23] A negative western blot is one 
in which no bands are present at molecular weights corresponding to HIV gene 
products.  
While the western blot is an excellent confirmatory test for HIV infection in 
patients with a positive or indeterminate EIA, it is a poor screening test. Among 
individuals with a negative EIA and PCR for HIV, 20 – 30% may show one or 
more bands on western blot. While these bands are usually faint and represent 
cross-reactivity, their presence creates a situation in which other diagnostic 
modalities (such as DNA PCR, RNA PCR, RNA assay, or p24 antigen capture) 
must be employed to ensure that the bands do not indicate early HIV infection. 
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The CD4+ T cell count is the laboratory test generally accepted as the best 
indicator of the immediate state of immunologic competence of the patient with 
HIV infection. This measurement, which is the product of the percent of CD4+ T 
cells (determined by flow cytometry) and the total lymphocyte count (determined 
by WBC and differential percent) has been shown to correlate very well with the 
level of immunologic competence. 
Patients with HIV infection should have CD4+ T cell measurements performed at 
the time of diagnosis and every 3 to 6 months thereafter. More frequent 
measurements should be made if a declining trend is noted. According to most 
guidelines, a CD4 count <350 cells/cmm is an indication for initiating 
antiretroviral therapy, and a decline in CD4 cell count of >25% is an indication for 
considering a change in therapy.  
 
INTRODUCTION OF ANTIRETROVIRAL THERAPY  
 The development of ART has been one of the most dramatic progressions in the 
history of medicine. Few other areas have been subject to such fast and short lived 
trends. Since the introduction of zidovudine as monotherapy in 1987, the treatment 
options have grown rapidly. Research has unleashed an array of drugs in each of 
the class of drugs and newer classes of drugs are fast coming upon the horizon. 
Currently the following classes of medications, target HIV : 
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NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs) 
Abacavir, didanosine, emtricitabine, lamivudine, stavudine, zidovudine , 
zalcitabine & tenofovir 
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 
(NNRTIs) 
Nevirapine, efavirenz, delavirdine are already existing 
PROTEASE INHIBITORS (PIs) 
Indinavir, saquinavir, ritonavir, nelfinavir, lopiinavir plus ritonavir, 
atazanavir  
FUSION INHIBITORS - Enfuvirtide 
INTEGRASE INHIBITORS – Raltegravir 
CCR5 ANTAGONISTS – Maraviroc 
Newer drugs and classes of drugs that have or about to join these popular drugs are  
New NRTIs – Elvucitabine, Nicavir, Racivir, Stampidine, Apricitabine,  
                        KP-1461  
New NNRTIs - Etravirine,  Rilpivirine 
New PIs – Darunavir, Brecanavir, tipranavir 
New CCR5 antagonists – Vicriviroc  
New integrase inhibitors – Elvitegravir 
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Drugs in the pipeline include – maturation inhibitors (Bevirimat) , attachment 
inhibitors, entry inhibitors,  anti-CD4 antibodies[28] (Ibalizumab).  
Mechanism of action: 
NRTIs-  structurally resemble human nucleosides that HIV uses to make viral 
DNA. The HIV reverse transcriptase enzyme can mistakenly incorporate the 
synthetic nucleoside analogue into the elongating strand of viral DNA during the 
reverse transcriptase process; once incorporated into viral DNA, the nucleoside 
anaologues act as chain terminators because they lack the 3′ hydroxy group 
required for chain elongation.  
NNRTIs – directly inhibit the proper functioning of the reverse tarnscrioptase 
enzyme. 
PIs – selectively bind to HIV protease and prevent this enzyme from performing its 
normal function of cleaving viral polyprotein precursors into individual functional 
proteins. 
FUSION INHIBITOR – works by binding to gp41 envelope protein of HIV to 
prevent it from mediating fusion of viral and cell membranes. 
INTEGRASE INHIBITORS -  HIV integrase is an enzyme which inserts viral 
DNA into the cellular genome through two catalytic reactions essential for  viral 
life cycle. Integrase inhibitors act at this step and disrupt the viral replication. 
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CCR5 antagonists -  HIV enters CD4+ T-cells via the chemokine receptor 5 
(CCR5) or CXC chemokine receptor 4 (CXCR4 coreceptor). These drugs act at 
this step and prevent the virus from entering the cells. Viral strains from patients 
with early stage disease usually use CCR5 coreceptors, whereas one-half of viral 
strains from patients with advanced immunosuppression enter via either the 
CXCR4 coreceptor alone, or both ("dual/mixed" tropic viruses).Because CCR5 
antagonists are not active against CXCR4 or dual-mixed tropic viruses, a 
pretreatment screening test should be used to assess viral tropism.[1]   
HAART – IT’S IMPLICATIONS 
 Zidovudine (ZDV/AZT) was the first nucleoside analog to be approved for the 
treatment of HIV infection in 1987.[29] In the late 1980's and early 1990's, 
monotherapy treatment trials using nucleoside reverse transcriptase inhibitors led 
to only transient clinical and immunologic improvement. ZDV led to clinical 
benefit and immunologic improvements in patients with advanced HIV disease; 
while in asymptomatic disease, no benefit of early versus deferred  monotherapy 
was seen. Two large trials (Delta trial, ACTG 175 trial) suggested that use of dual 
nucleoside analog therapy was superior to monotherapy in reducing the combined 
endpoints of declining CD4 cell counts, onset of AIDS, or death. The ACTG 320 
trial was a landmark study, which proved that triple therapy with two NRTIs plus a 
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protease inhibitor was superior to dual NRTI therapy alone in reducing AIDS-
related complications and deaths. With this major breakthrough in clinical 
management of HIV infection, the three-drug therapy (including two different 
classes of drugs) was used to lower HIV RNA below the level of detection. This 
approach to treatment dramatically reduced the development of drug resistance and 
frequently led to both durable virologic suppression and long-term clinical 
benefits.[30]   
The term ‘highly active antiretroviral therapy’ or combination antiretroviral 
therapy (ART) gained widespread acceptance since 1996 when the new class of 
protease inhibitors were approved for use and is the corner stone of management of 
patients with HIV infection. Since then HAART has maintained itself as the first 
line of defence against HIV infection. Traditionally HAART consists of 
combination of three or more drugs in any of the following class, not necessarily in 
the same order: NRTI + NRTI + NRTI / NNRTI / PI. In the earlier phase HAART 
was shown to reduce, the incidence of AIDS defining conditions in Europe from 
30.7 to 2.5 per 100 patient years between 1994 and 1998 which was replicated in 
USA and elsewhere. [31]   
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HAART adverse effects  
In 1997, the FDA published the first warning about the development of diabetes 
mellitus associated with the use of PIs.[26]  Realization about lipodystrophy, a new 
term, followed by mitochondrial toxicity.[27] Reinforced the dictum: all effective 
drugs have side effects. The initial euphoria over eradication of viral load with 
HAART has turned bleak with HIV remaining detectable in latently infected cells, 
even after long term suppression and the most recent estimate for eradication of 
these cells standing at 73.3 years .[32] This has led us to coexist with the spectrum of 
dramatic improvement in the standard of living standard of HIV infected 
individuals on one hand and hitherto unheard of toxicities of associated with daily 
consumption of loads of drugs on a long term basis. Treatment of HIV infection 
has become a complicated balancing act between the benefits of durable HIV 
suppression and the risks of drug toxicity. Common side effects associated with 
HAART are [1]:                                                      
ZDV - Anemia, granulocytopenia, myopathy, lactic acidosis, hepatomegaly with 
steatosis, headache, nausea 
ddI - Pancreatitis, peripheral neuropathy, abnormalities on liver function tests, 
lactic acidosis, hepatomegaly with steatosis 
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ddC - Peripheral neuropathy, pancreatitis, lactic acidosis, hepatomegaly with 
steatosis, oral ulcers 
d4T - Peripheral neuropathy, pancreatitis, lactic acidosis, hepatomegaly with 
steatosis, ascending neuromuscular weakness, lipodystrophy. 
Abacavir - Hypersensitivity reaction (can be fatal), fever, rash, nausea, vomiting, 
malaise, fatigue, loss of appetite. 
Nevirapine - Skin rash, hepatotoxicity. 
Efavirenz - Rash, dysphoria, elevated liver function tests, drowsiness, abnormal 
dreams, depression. 
PIs - Diarrhea, nausea, headaches, hyperglycemia, fat redistribution, lipid 
abnormalities. 
Maraviroc - Hepatotoxicity, nasopharyngitis, fever, cough, rash, abdominal pain, 
dizziness, fever, musculoskeletal symptoms. 
Raltegravir - Nausea, rash. 
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Immune Reconstitution Inflammatory Syndrome (IRIS) 
Following the initiation of effective ART, a paradoxical worsening of preexisting, 
untreated, or partially treated opportunistic infections may be noted in the form of 
localized lymphadenitis, prolonged fever, pulmonary infiltrates, increased 
intracranial pressure, uveitis, and Graves' disease. These IRISs are particularly 
common in patients with underlying untreated mycobacterial infections. They are 
seen in 10–50% of patients, depending upon the clinical setting, and are most 
common in patients starting therapy with CD4+ T cell counts <50 cells/cmm, high 
viral load who have a precipitous drop in HIV RNA levels following the initiation 
of HAART.[1]  Signs and symptoms may appear anywhere from 2 weeks to 2 years 
after the initiation of HAART. Underlying mechanism appears to be related to a 
phenomenon similar to type IV hypersensitivity reactions and reflects the 
immediate improvements in immune function that occur as levels of HIV RNA 
drop, CD4+ cell count increase  and the immunosuppressive effects of HIV 
infection are controlled. In severe cases, the use of immunosuppressive drugs such 
as glucocorticoids may be required to blunt the inflammatory component of these 
reactions while specific antimicrobial therapy takes effect. Data from resource-
limited countries on TB IRIS is scarce; a rate of 8% was reported from India.[85] 
Crisis seem to be alarming in third world nations, where the proportion of HIV/TB 
IRIS is reportedly high, ranging from 11% to 43%.[86-89] 
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Monitoring of patients with HIV 
CD4+ T Cell Counts 
It is the laboratory test generally accepted as the best indicator of the immediate 
state of immunologic competence of the patient with HIV infection. This 
measurement has been shown to correlate very well with the level of immunologic 
competence. CD4+ T cell measurements are performed at the time of diagnosis and 
every 3–6 months thereafter. More frequent measurements should be made if a 
declining trend is noted. According to most guidelines, a decline in CD4+ T cell 
count of >25% is an indication for considering a change in therapy. Once the 
CD4+ T cell count is <200/cmm patients should be placed on a regimen for P. 
jiroveci prophylaxis, and once the count is <50/cmm primary prophylaxis for MAC 
infection is indicated. 
HIV RNA Determinations 
Plasma HIV RNA (viral load) has become an essential component in the 
monitoring of patients with HIV infection. The two most commonly used 
techniques are the RT-PCR assay and the bDNA assay. Both assays generate data 
in the form of number of copies of HIV RNA per milliliter of serum or plasma. 
Measurements of changes in HIV RNA levels over time have been of great value 
in delineating the relationship between levels of virus and rates of disease 
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progression, the rates of viral turnover, the relationship between immune system 
activation and viral replication, and the time to development of drug resistance. 
Measurements of plasma HIV RNA levels should be made at the time of HIV 
diagnosis and every 3–6 months thereafter in the untreated patient. In general, most 
guidelines suggest that therapy be considered in patients with >100,000 copies of 
HIV RNA per milliliter. Following the initiation of therapy or any change in 
therapy, plasma HIV RNA levels should be monitored approximately every 4 
weeks until the effectiveness of the therapeutic regimen is determined by the 
development of a new steady-state level of HIV RNA. During therapy, levels of 
HIV RNA should be monitored every 3–4 months to evaluate the continuing 
effectiveness of therapy. 
HIV Resistance Testing 
The availability of multiple ARV drugs as treatment options has generated a great 
deal of interest in the potential for measuring the sensitivity of an individual's HIV 
virus to different ARV agents. HIV resistance testing can be done through either 
genotypic or phenotypic measurements These tests are quite good in identifying 
those ARV agents that have been utilized in the past and suggesting agents that 
may be of future value in a given patient. Drug resistance testing in the setting of 
virologic failure should be performed while the patient is still on the failing 
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regimen because of the propensity for the pool of HIV quasispecies to rapidly 
revert to wild-type in the absence of the selective pressure of ARV therapy. 
Resistance testing enhances the short-term ability to decrease viral load by ~0.5 log 
compared to changing drugs merely on the basis of drug history. In addition to the 
use of resistance testing to help in the selection of new drugs in patients with 
virologic failure, it may also be of value in selecting an initial regimen for 
treatment of therapy-naïve individuals. This is particularly true in geographic areas 
with a high level of background resistance. 
HAART in resource poor settings 
     With the wide spread use of HAART, dramatic decrease in the morbidity and 
mortality associated with HIV infection throughout the developed world was seen.  
As a result, the gap between outcomes for HIV-infected persons in the developed 
world and outcomes for those in the developing world began to widen. It was seen 
that more people with HIV(> 95% of total HIV infected population ) were living in 
developing countries and the epidemic continuing, where ART was still 
inaccessible due to the high cost of drugs, poverty, illiteracy and ignorance.[36] 
There were lot of concerns regarding the feasibility of ART programs in resource 
poor settings and also  adherence to therapy. Providing antiretroviral therapy 
involves more than just dispensing of medications, and a variety of problems, 
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including the prevailing limitations in health infrastructure and human resources in 
the countries most heavily affected by the HIV/AIDS pandemic, have been 
mentioned as reasons to expect failure of treatment programs. [33] With all these 
factors, the need to close the treatment gap was declared a global public health 
emergency in 2003 by WHO. The "3 by 5" initiative, launched by UNAIDS and 
WHO in December 2003, was a global strategy to provide antiretroviral therapy to 
three million people living with HIV/AIDS in 50 developing countries by the end 
of 2005. By the end of 2005 the WHO estimated that there were just over 1.3 
million people receiving antiretroviral therapy (ART) in low-income and middle-
income countries, representing 20% of the 6.5 million estimated to need it. This 
program was subsequently replaced by The Global Fund for AIDS, Tuberculosis 
and Malaria as well as bilateral support like the President's Emergency Plan for 
AIDS Relief (PEPFAR). By the end of 2007, the number of AIDS patients 
receiving ARVs had risen from less than 50,000 to 2.2 million over a five-year 
period in low and middle income countries in sub-Saharan Africa.[7] The 
development of generic medications has been an important advance in making 
ART available in resource-poor countries.[34]  
Indications for starting ART : All HIV positive persons with CD4 count less than 
200 cells/cmm, irrespective of clinical stage, all  HIV positive persons in stage 4 
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disease irrespective of CD4 count, patients in stage 3 with less than 350 
cells/cmm.[35] 
 Recommendations for initiating ART in adults and adolescents in accordance with 
clinical stages and the availability of immunological markers.[36] 
  
Drugs recommended : The public health approach to ART scale-up in resource-
limited settings aims to support the development of treatment programmes that can 
reach as many people as possible. Countries are encouraged to use the public 
health approach to support and facilitate wider access to ART. Countries select a 
firstline regimen and a limited number of second-line regimens, for those 
individuals who cannot tolerate or fail the first-line. Firstline regimens include 
2NRTI+1NNRTI. It is recommended that PIs be reserved for second-line therapy 
because their use in an initial treatment regimen essentially rules out second-line 
options in resource poor settings.[36] PIs as initial therapy with a standard dual 
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NRTI backbone are an option for the treatment of viral types with intrinsic 
resistance to NNRTIs (e.g. HIV-2). Availability of second line ART drugs are  
limited to few resource poor countries due to the high cost of therapy and also 
sophisticated laboratory monitoring (viral loads, mutation testing) . 
Treatment failure: following definitions of ART failure are used [36]: 
   
Indian scenario 
The free ART initiative in India was launched on 1st April, 2004. The guide lines 
for ART in resource constraints settings were framed by NACO during a national 
consultation in january 04 and were further modified in December 2005 and 
2006.[12] Indications for starting are the same as those in other resource constraint 
settings shown in the above table. Currently, the national programme provides the 
following first-line regimen drugs: stavudine (30mg), lamivudine (150mg), 
zidovudine (300mg), nevirapine (200mg), efavirenz (600mg) either singly or as 
fixed drug combinations. Recommended first-line antiretroviral regimens are: 
Zidovudine + lamivudine + nevirapine  Æ  preferred first line regimen. 
Zidovudine + lamivudine + efavirenz  alternate first line regimen 
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Stavudine + lamivudine + nevirapine / efavirenz          alternate first line regimen 
Tenofovir  + lamivudine + nevirapine / efavirenz and zidovudine + lamivudine + 
tenofovir  are other options available under special considerations.          
Second line drugs were not available under the national programme until may 2008 
in India, after which they were made available only in select larger centres.   
HAART outcomes in resource poor settings:  
Most of the reports/studies are from African continent and few from asian 
continent. 
1) Clinical outcomes :  In all studies, clinical outcomes improved with 
HAART.  
a) Weight gain : Among 14 studies that reported on weight trends, the 
weight gain ranged from 1.5–10.7 kg, showing an increase in weight with 
treatment. [37-51] 
b)  The mortality rate ranged from 0% – 27%. [37-51, 53, 55, 57–65, 67-70] 
c) Three studies presented the probability of survival at the ends of their 
investigations, which ranged from 70% to 86.3%. [55, 56, 67] 
d) Adverse events to drugs occurred in 14.3%–80.2% of patients in studies. 
[37-40, 54, 57, 61]Three studies reported that 10%–62% of patients experienced 
specific types of adverse events, with dizziness, anemia, rash, 
neutropenia, and peripheral neuropathies occurring most frequently. 
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e) Opportunistic infections: Five studies reported that 5%–15% of patients 
had developed either CDC category C HIV-related events, AIDS-
defining  illnesses, or opportunistic infections generally. [38,49,51,58,60] In 
the latter case, the opportunistic infections that most commonly emerged 
were tuberculosis and candidiasis. Thirty percent of Senegalese patients 
taking a once-daily regimen were hospitalized for opportunistic 
infections. [37] Two other studies found that 5% of patients had to change 
treatments or withdraw from the study as a result of tuberculosis. [54, 59] 
One study determined that opportunistic infections decreased by 68% due 
to HAART.[57] 
1) Laboratory outcomes :  
a) CD4 cell counts : Patients were at an advanced stage of HIV at the start 
of therapy as indicated by initial CD4 count of less than 50 cells/cmm in 
many studies. Most of the studies demonstrated gain in CD4 counts. 
Increases in the CD4 cell count ranged from 74 to 440 cells/mm3 at the 
ends of studies, with median increases of 138.6 cells/mm3. [40-43,45,46, 52,55- 
60] Only few studies reported CD4 cell count increase of  less than 100 
cells/mm3 over the duration of treatment follow-up [38, 39, 44, 47, 54] 
b)  viral loads : Most of the studies demonstrated a decline in viral load, 
undetectability ranged from less than 50 to less than 500 copies/mL. In 
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the 21 studies that reported viral load outcomes, the percentage of 
patients who had viral loads that were less than the cut off values by the 
end of the study varied from 32% to 95%, with a median of 73% of 
patients achieving undetectability. [37-54, 57, 58, 61, 65–68] ART resulted in an 
HIV RNA viral load suppression in 60%–70% of individuals at time 
points up to month 18. This proportion of individuals who had viral 
suppression is similar to that observed in developed countries, even in 
clinical trials. [67,72-74] 
2) Adherence to treatment: Adherence to treatment was highlighted as an issue 
in 10 studies. The percentage of patients who took more than 95% of 
treatment doses ranged from 68% to 99%.[37–39, 45, 47, 54] Oyugi et al. 
determined an average adherence rate of 85% using 4 different methods (pill 
count, self-report, visual analogue scale, and Medication Event Monitoring 
System technology). [40]  A Nigerian study that compared cohorts aged less 
than 55 years with cohorts aged more than 55 years found that the older 
patients had an adherence rate of 91%, whereas the younger patients had a 
reported adherence rate of 76%. [49] 
3) Retention :  Eighteen studies documented retention of cohorts as ranging 
from 53.8% to 100%  over a mean duration of follow-up of 12 months. [37–43, 
46–49, 51, 53,55, 57, 59, 60, 62, 63, 65] 
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Conclusions :  Review of studies analyzing ART programs in economically 
backward countries provides promising evidence for the administration of HIV 
treatment in resource-poor settings. Essentially all studies reported high rates of 
adherence and optimistic outcomes comparable to those of developed countries. [71] 
  Pooled data from these studies are encouraging, because ~70% of the patients had 
undetectable HIV viral loads (defined as an HIV RNA level of less than 400 
copies/mL) at month 6 after initiation of antiretroviral therapy, and 57% at month 
12. These virologic response rates approximate the rates found in similar clinical 
trials that, until now, have been conducted mostly in developed countries. Data 
also suggest that patients who received antiretroviral therapy free of charge had an 
almost 30% higher chance of having an undetectable HIV viral load after therapy 
than did patients who had to pay for all or part of their drug therapy. [75] 
Preliminary results show the major benefits brought by HAART in resource-poor 
settings, even for patients at an advanced stage of AIDS. Patients show regular 
attendance, and immunological and virological responses indirectly indicate a high 
level of individual drug adherence. Regardless of the need for operational research, 
these results support the belief that treating severely immunocompromised AIDS 
patients is feasible in various settings, including in peripheral health facilities, as 
has also recently been reported by Ugandan and Senegalese national initiatives.[76]  
Observational data presented by MSF at the International AIDS Conference in 
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Bangkok included findings for 112,000 adults who have been treated in 31 MSF 
programs in 16 resource poor countries, which demonstrated that most patients 
experienced a 3–5 kg weight gain and an increase of 135 cells/mL in CD4 cell 
counts at month 12 of antiretroviral treatment. [77] Similarly, Zhou et al. published 
findings from an observational cohort of antiretroviral-naive Asian patients 
receiving HAART and found 69% of patients showed a virologic response (i.e., 
had an HIV RNA load of < 400 copies/ mL) at month 6. [78]  The WHO guidelines 
provide an appropriate framework, as reflected by the ability for the studies 
reviewed to employ recommended regimens and regular monitoring strategies The 
results demonstrated have strong implications for current treatment initiatives, 
including those administered by national governments and the President’s 
Emergency Plan for AIDS Relief. 
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                                    MATERIALS AND METHODS 
Settings  
ART CENTRE, Institute of internal medicine, 
Madras Medical College and Government General Hospital  
Chennai - 600 003. 
Ethical approval 
 Obtained  
Study duration 
This study was conducted for a period of eighteen months from 1st January 2007 to 
June 30, 2008. 
Study Design  
To evaluate the effectiveness of  HAART in antiretroviral-naïve adults, attending 
the ART centre;  a single centre prospective cohort study.  
Inclusion criteria 
All HIV positive patients started on HAART within 2 months of diagnosis. 
attending ART centre from January 1st 2007. 
Age > 18 yrs. 
In WHO clinical stage III / stage IV or with CD4 count < 200 cells/cmm. 
Patients with no history of antiretroviral therapy (ART naïve). 
46 
 
Exclusion criteria 
All HIV positive patients not started on ART. 
Patients not started on ART for more than 2 months from diagnosis.  
Age < 18 yrs. 
In WHO clinical stage I/II or with CD4 count > 200 cells/cmm.  
On previous antiretroviral therapy at any point (non ART naïve). 
Laboratory Methods  
 Testing for HIV 1 and 2 had been performed on each patient using ELISA 
technique. For those with positive results on the first ELISA test, a second more 
specific ELISA was used for confirmation. Western blot technique was not used 
for confirmation. Full blood count, blood sugar, urea, creatinine, liver function 
tests were done. CD4 count was performed for all HIV positive patients using flow 
cytometry. Chest X ray and other tests were done only when there was a clinical 
suspicion and not routinely.  
 
METHODS 
Study population    
A total of 461 patients were enrolled for the study from the population of HIV 
infected patients who attended the ART clinic, Institute of Internal Medicine, from 
the period between 1st January 2007 to December 31st 2007. 
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221 patients were excluded as per exclusion criteria. The remaining 240 patients 
were selected for the study, who satisfied all the inclusion and exclusion criteria, 
were followed till june 30th 2008. Written consent was obtained from all patients 
participating in the study.    
All patients with HIV referred to ART centre were subjected to a detailed clinical 
history regarding their marital status, risk factors for HIV, possible route of 
acquisition, history of opportunistic infections, sexually transmitted infections, 
previous HIV testing,  medication/drug  use, comorbidities like diabetes, 
hypertension, hepatitis B/C, history of vaccination,  allergy,  history of 
smoking/alcoholism. A thorough physical examination done for screening and 
clinical staging.  
    Initial investigations included complete blood count, renal function tests, liver 
function tests, CD4 count, sputum examination for TB bacilli and chest x ray for 
those with cough 
     Patients who were in stage III/IV of WHO staging and those with CD4 count 
less than 200 irrespective of stage were eligible for therapy.  ART  was started for 
these patients before which they were given counseling regarding the nature of the 
disease, need for life long therapy, effects and side effects of therapy, need for durg 
adherence. Consultation frequency was determined by clinical protocol; fortnightly 
for the first month and then monthly. They were seen more frequently if clinically 
48 
 
indicated. CD4 count and other investigations mentioned above were done at 
baseline and every six months thereafter. Standardized flow chart algorithms for 
the management of adverse events were in place as per NACO guidelines. 
     Eligible patients were started on triple therapy including 2NRTIs + 1NNRTI. 
Stavudine,  lamivudine, nevirapine were the drugs routinely prescribed.  Single-
drug substitutions were permitted: zidovudine  could be substituted for stavudine, 
and efavirenz could be substituted for nevirapine  when they developed some 
adverse effects to routine drugs, when they were on concomitant ATT or when 
routine drugs were out of stock. HIV-infected adults and adolescents with 
pulmonary tuberculosis and a CD4 T-cell count of more than 200 per cubic 
millimeter were treated for tuberculosis, and initiation of antiretroviral therapy was 
deferred. In patients with tuberculosis who had a CD4 T-cell count less than 200 
per cubic millimeter, antiretroviral therapy was initiated after the completion of 
two weeks of tuberculosis therapy. Second line drugs were not available at our 
ART centre. When patients missed 3 consecutive visits, two or more attempts were 
made to contact them before considering them lost to follow up. Once HAART 
was initiated, patients returned to the ART centre at monthly intervals for medical 
evaluation, adherence education, and medication refills. Adherence to therapy was 
checked by pill count, returning of empty contrainers and self reporting at every 
follow up.  
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     Clinical services were provided at the ART centre by a team comprising  of 
doctors, nurses and counsellers with good continuity of care. A strong patient 
centred approach was used to promote adherence. This included a comprehensive 
counseling infrastructure providing for one to one individual counselling with 
trained counselors.  
 
 
FINANCIAL SUPPORT: nil. 
 
CONFLICT OF INTEREST: nil. 
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Statistical analysis: 
      Data analysis was done with use of SPSS, version 10. Descriptive statistics 
were used to calculate the frequency, mean, median, and standard deviation. To 
examine the linear trend of the proportions, trend chi-square was used and to find 
the test  of  association chi-square was computed. For all normally distributed 
variables, Student’s t test was used to determine the significant mean difference in 
various groups. Survival times were calculated from the date of the participant’s 
initiation of ART to the last day of study follow-up for each participant. Kaplan-
Meier survival analysis was performed to determine the mean and median 
durations of survival in relation to the demographic variables, CD4 cell count, and 
antiretroviral therapy. Tarone-Ware statistics were used to test the equality of the 
survival distributions for all of the variables. Multivariate Cox regression analyses 
for all factors relating to survival of patients were done. 
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OBSERVATION AND RESULTS 
The analysis included 240 adults who were selected after considering the inclusion 
and exclusion criteria and started on ART. The median follow up time was ten 
months for all the 240 patients and 14 months for those surviving at the end of 
study. 
Baseline characteristics 
     Baseline characters of 240 ART naïve patients are given in table below. More 
men (73.3%) than women accessed treatment. Median age of the patients was 36 
years. Most (90%) were married. Predominant route of acquisition of HIV was 
heterosexual (97.1%). Patients began treatment with advanced disease as 
evidenced by low cd4 count, advanced WHO stage. The median baseline CD4 
lymphocyte  count was 122cells/cmm. 84 patients (35%) were in WHO stage IV, 
114 patients (47.5%) were in stage III, 29 (12.1%) were in stage II, 13 patients 
(5.4%) were in stage I. 
Antiretroviral treatment initiation 
70.8% of patients were started on stavudine, lamivudine, nevirapine regimen; 
17.5% started on zidovudine, lamivudine, nevirapine regimen; 10% started on 
stavudine, lamivudine, efavirenz regimen; 1.7% started on zidovudine, lamivudine, 
efavirenz regimen. 
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  Base line characteristics of patients enrolled in the study 
Characteristic                                             Value   
Total patients enrolled 240 
Male  176 (73.3%) 
Female  64 (26.7%) 
Median age  36 yrs  
Married 216 (90%) 
Unmarried  24 (10%) 
Route of acquisition of HIV  
Heterosexual 233 (97.1%) 
Male having sex with male (MSM) 4 (1.7%) 
Intravenous drug use (IVD) 2 (0.8%) 
Blood transfusion (BT) 1 (0.4%) 
WHO stage  
Stage I 13 (5.4%) 
Stage II 29 (12.1%) 
Stage III 114 (47.5%) 
Stage IV 84 (35%) 
Median body weight in kg  48 (min-max of 26 to 74) 
Median body mass index 17.78 (min-max of 11.56 to 29.55) 
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Survival and patient retention at the time of data analysis 
At the time of analysis, of 240 patients enrolled in the study, 162 (67.5%)  were 
still under follow up, 35 patients (14.5%) were lost for follow up and 43patients 
(17.9%) died. Of the 35 patients lost to follow up, 9 patients were transferred 
within 3 months of starting ART, 1 patient was transferred at 5 months. The 
whereabouts of rest 25 patients were not traceable, and were lost within 3 months 
after start of therapy, and it was not known if they were alive or dead at the time of 
analysis. The main reason for lost to follow up was their leaving the city to return 
to their native villages.  
Of 43 deaths, 8 (18.6%) were due to pneumocystis jiroveci pneumonia, 3 (6.9%) 
due to cryptococcal meningitis, 11 (25.5%) due severe wasting of which 5 had 
Median CD4 cell count/cmm  122 (min-max of 5 to 495) 
Median Hemoglobin in g/dl 9.5 (min-max of 5.5 to 15) 
Initial ART regimen –  No. % 
stavudine, lamivudine, nevirapine 170 (70.8%) 
stavudine, lamivudine, efavirenz 24 (10%) 
zidovudine, lamivudine, nevirapine 42 (17.5%) 
zidovudine, lamivudine, efavirenz 04 (1.7%) 
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chronic diarrhoea, 13 (30.2%) died of tuberculosis of which 4 had disseminated 
TB, 5 had meningitis, 4 had pulmonary TB, 1 (2.3%) died of squamous cell 
carcinoma of lung, 1 died of HIV encephalopathy, 1 due to severe bacterial 
pneumonia, 3 (6.9%) died of massive haematemesis of which 1 had extrahepatic 
portal vein obstruction with hepatitis B, 1 had liver cirrhosis with hepatitis B and 
one more with hepatitis C.  Factors present at baseline which were predictors of 
death were presence of AIDS defining illness, low CD4 count, low body mass 
index and low haemoglobin. Of the deaths due to HIV, 35 (81.3%) occurred within 
the first 3 months of starting therapy yielding an estimate of survival of 79% for all 
the patients followed. Eighty three patients began treatment with a CD4 count of 
less than 100 cells/cmm. Estimates of survival at 18 months stratified by initial cd4 
lymphocyte count were 56.7% for those initiating treatment with less than 50 
cells/cmm and 82.9% for those with more than 50 cells/cmm.  
 
CD4 T cell response:  
103 (42.9%) patients had CD4 count less than 100, 97 of them had CD4 count 
between 100 to 200 cells/cmm and 40 (16.7%) had more than 200 cells/cmm. 
Median CD4 count at baseline was 122, at 6 months 277 and at 12 months 338. Of 
the 205 patients only 3 patients had a decrease in CD4 count from baseline. Mean 
CD4 cell gain at 6 months was 162 cells/cmm (95% CI, 140 to 183) and gain at 12 
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months, from baseline was 225.7 cells/cmm (95% CI 193 to 258 cells/cmm) which 
was very significant (p=0.000). 32.5% of patients in <100 count group died 
whereas around 13% patients died in the other two groups. The proportion of 
patients surviving increasing significantly (p<0.005) as the cd4 count increased 
from baseline.    
                
 
 
 
 
 
 
 
 
 
 
CD4_0   Æ CD4 count at baseline (0 months)                    CD4_6  Æ CD4 count at 6 months 
CD4_12 Æ CD4 count at 12 months 
  
CD4 Groups Number of  Pts  Percentage  
< 100 103 42.9 
100 – 200 97 40.4 
> 200 40 16.7 
Total  240 100 
Paired Samples Test
-162.07 136.84 10.78 -183.37 -140.78 -15.029 160 .000
-59.23 109.09 12.05 -83.20 -35.26 -4.917 81 .000
-225.74 156.51 16.32 -258.15 -193.33 -13.835 91 .000
CD4__0 - CD4__6 Pair 1
CD4__6 - CD4___12Pair 2
CD4__0 - CD4___12Pair 3
Mean Std. Deviation
Std. Error
Mean Lower Upper
95% Confidence
Interval of the
Difference
Paired Differences
t df Sig. (2-tailed)
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                              CROSS TABLE        
 
 
 
 
 
 
 
Weight gain : 
 Of 240 patients 130 (54.2%) had BMI less than 18;  83 patients (34.6%)  had BMI 
between 18 - 22.9 and 27 patients (11.3%) had BMI more than 23. Mean weight 
gain at 6 months was 3.73 kgs and mean weight gain at 12 months from baseline 
was 4.43 kgs with almost all patients showing an increase in weight which was 
statistically significant (P=0.000). 25.5% of patients died in BMI group <18 
whereas that of the other two goups were 11.8% and 8% respectively, which shows 
that the proportion of survival is increasing as BMI increases and the linear 
association,   is statistically significant. 
 
 
 
 
CD4 Groups Died Survived Total 
< 100 27 (32.5%) 56 (67.5%) 83  
100 - 200 11 (12.8%) 75 (87.2%) 86 
> 200 5 (13.9%) 31 (86.1%) 36  
Total  43 (21%) 162 (79%) 205  
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Patient cohort divided into BMI Groups: 
BMI Groups Number of patients percentage 
< 18 119 49.6 
18 – 22.99 83 34.6 
> 23 27 11.3 
Missing data 11 4.6 
Total  240 100 
 
 
 
               WT_0  Æ weight at baseline (0 months)               WT_6  Æ weight at 6 months      
              WT_12 Æ weight at 12 months      
 
 
 
 
Paired Samples Test
-3.74 4.93 .37 -4.47 -3.00 -10.036 174 .000
-.37 4.11 .45 -1.26 .52 -.823 83 .413
-4.43 6.37 .67 -5.77 -3.10 -6.602 89 .000
WT_0 - WT_6 Pair 1 
WT_6 - WT_12 Pair 2 
WT_0 - WT_12 Pair 3 
Mean Std. Deviation
Std. Error
Mean Lower Upper 
95% Confidence 
Interval of the 
Difference
Paired Differences
t df Sig. (2-tailed)
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CROSS TABLE: 
 
 
 
 
 
 
 
Haemoglobin response:   
Of  240 patients, data was available for 201 patients, of which 14 patients were in 
Hb less than 7g/dl group, 109 patients were in Hb 7 to 10g/dl group and 78 patients 
were in Hb more than 10g/dl group. Mean gain in Hb at 6 months was 0.7g/dl and 
mean gain at 12 months from baseline was 1.28g/dl with almost all patients 
showing an increase in Hb which was statistically significant (P=0.000). 71.4% of 
patients died in less than 7 Hb group, and 30.3% died in Hb 7-10 group, where as 
none died in more than 10 Hb group, which shows that proportion of patients 
surviving increased as haemoglobin  increased, which is statistically significant 
 
 
 
BMI Groups died survived total 
<18 24 (25.5%) 70 (74.5%) 94 
18 – 22.99 9 (11.8%) 67 (88.2%) 76 
> 23 2 (8%) 23 (92%) 25 
Total  35 (17.9%) 160 (82.1%) 195 
59 
 
 
 
 
 
                       CROSS TABLE 
          
 
 
 
 
 
 
Opportunistic infections:  
167 (69.58%) of total 240 patients developed one or the other opportunistic 
infection. Of these 167 patients, 81(48.5%) had some opportunistic infection at the 
time of diagnosis of HIV, 50 of whom had AIDS defining illness. The rest 86 
patients (51.5%) developed some opportunistic infection after the start of ART. Of 
Hemoglobin died survived Total 
< 7 10 (71.4%) 4 (28.6%) 14 
7 - 10 33 (30.3%) 76 (69.7%) 109 
> 10  78 (100%) 78 
Total 43(21.4%) 158 (78.6%) 201 
Paired Samples Test
-.706 1.171 033E-02 -.884 -.528 -7.815 167 .000
-.824 .666 944E-02 -.962 -.686 -11.865 91 .000
-1.284 1.283 .134 -1.549 -1.018 -9.595 91 .000
HB_0 - HB_6MPair 1
HB_6M - HB_1Pair 2
HB_0 - HB_12Pair 3
Mean Std. Deviation
Std. Error
Mean Lower Upper
95% Confidence
Interval of the
Difference
Paired Differences
t df Sig. (2-tailed)
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them 27 patients developed AIDS defining illness, of which except for 3 patients, 
the rest(24) developed infection within 2 months of start of therapy. The most 
common AIDS defining infection was extrapulmonary TB, pulmonary TB was not 
considered as AIDS defining infection.   
Tuberculosis :  
66 patients (27.5%) of  240 had TB, of which 29 patients were detected to have TB 
at diagnosis and the rest 37 developed new onset TB during the course of therapy. 
Of these 37 patients, 13 patients (45.9%) developed TB within 4 months of 
initiation of therapy. Of the total 66 patients, 28 (42.4%) developed pulmonary TB, 
33 patients (50%) developed extra pulmonary TB and 5 patients (7.5%) developed 
disseminated TB. Of the 66 patients who developed TB, 13 patients died, 10 were 
lost to follow up and the rest were declared cured.15 patients (22.7%) of 66 had 
features suggestive of immune reconstitution inflammatory syndrome in the form 
of worsening of symptoms like increase in size of lymph nodes, increase in fever 
and cough, though it was not severe enough to warrant stopping of ART.  
First line medication changes and toxic effects : 
28 patients (11.6%) of a total of 240 started on ART, changed their initial regimen. 
Of them 15 patients (53.5%) changed as they developed new onset TB, 12 patients 
(42.8%) changed their initial regimen as they developed adverse reaction to ART. 
Nevirapine was the drug which caused most adverse effects, mainly skin rash, 
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which 6 patients developed of which 2 had grade III reaction and the rest grade II; 
3 patients developed severe anaemia (grade III) and 1 patient developed severe 
vomiting (grade III) after being started on zidovudine and 2 patients developed 
peripheral neuropathy induced by stavudine. ; 1 patient (3.5%) on zidovudine 
based regimen changed, as he developed severe anaemia (drug induced) and new 
onset TB. 67.8% of patients changed their initial regimen, within 3 months of the 
start of therapy. 
 
Kaplan meire survival analysis :  
The median survival time for all patients under follow up was 14 months (95% CI 
13 – 15) as shown below in the fig.  
                     
Survival Function
FLUP_MONTH
20100
C
um
 S
ur
vi
va
l
1.2
1.0
.8
.6
.4
.2
0.0
-.2
Survival Function
Censored
 Follow up month    
62 
 
 
The mean survival time for the patients who had cd4 <50 at the baseline was 12 
months (95% CI 10 - 14); in case of cd4>50, mean survival time was 13 months 
(95% CI 12 - 14), and there was no statistically significant difference in the 
survival distribution (p>0.05) which is shown in the fig. below. 
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Adherence to therapy :  
More than 95% of patients who were under follow up until till the end of study 
took more than 95% of doses, which was confirmed by self reporting and pill count 
Follow up month 
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at the each visit, which implies a very high adherence to therapy. Most common 
reason for non-adherence was due to them going out of station for work.  
Multivariate analysis:  
There was no significant(p>0.05) association b/w gender, age group, WHO 
staging, cd4 counts, and survival on multivariate analysis.  
The odds ratio of mortality was 1.3 times higher in cd4 <100 group compared to 
the group who had cd4>200 and this is the same for the cd4 group 100 to 200, 
which is not statistically significant. 
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Discussion :  
HIV infection/AIDS is a global pandemic, with cases reported from every country 
throughout the world with about 35 million deaths already and 33 million infected 
individuals. HAART is a novel treatment available since 1996, which has 
dramatically changed the evolution of HIV infection. With the introduction of this 
therapy HIV has been changed from a fatal condition to a chronic manageable 
illness. In developed countries, marked advances in HIV antiretroviral therapy 
have resulted in significant increase in the survival rate and quality of life of HIV-
infected individuals. As a result, the gap between outcomes for HIV-infected 
persons in the rich developed world and the poor developing world began to 
widen. The need to close this treatment gap was declared a global public health 
emergency by WHO in 2003. The "3 by 5" initiative, launched by UNAIDS and 
WHO in December 2003, was a global strategy to provide antiretroviral therapy to 
people in developing countries. From then on HAART became available in 
resource poor countries. The early outcomes of HAART in our population in this 
study are as follows: 
More men (73.3%) than women accessed treatment and  median age of the patients 
was 36 years which is similar to a number of studies in resource poor 
settings,[37,43,44,84]  Patients began treatment with advanced disease as evidenced by 
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low cd4 count, advanced WHO stage. The median baseline CD4 lymphocyte  
count was 122cells/cmm and 82.5% of the study population was in stage III and IV 
disease. 70.8% of patients were started on stavudine, lamivudine, nevirapine 
regimen; 17.5% started on zidovudine, lamivudine, nevirapine regimen; 10% 
started on stavudine, lamivudine, efavirenz regimen; 1.7% started on zidovudine, 
lamivudine, efavirenz regimen. 
Survival outcomes: 
Of 240 patients enrolled in the study, 162 (67.5%) were alive and 43patients 
(17.9%) died. Factors present at baseline which were predictors of death were 
presence of AIDS defining illness, low CD4 count, low body mass index and low 
haemoglobin. Of the deaths due to HIV, 35 (81.3%) occurred within the first 3 
months of starting therapy yielding an estimate of survival of 79% for all the 
patients followed. Estimates of survival at 18 months stratified by initial cd4 
lymphocyte count were 56.7% for those initiating treatment with less than 50 
cells/cmm and 82.9% for those initiating treatment with more than 50 cells/cmm. 
These results are comparable with data from observational settings in both 
developed and developing countries. In spite of differences in reporting, patients in 
this study initiated therapy with almost same stage of disease as other studies,[37,84] 
and using survival as an endpoint, have responded to treatment at least as well, as 
them.[37,84]The median survival time of patients with cd4 count less than 50 
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cells/cmm of 12 months in this study is similar to that seen in other studies. [81] 
Survival outcomes in this study are just lower to those reported for patients 
initiating ART with low cd4 lymphocyte counts in two observational studies in 
Canada and the USA,[80]although the observation periods for these cohorts include 
years where dual therapy was provided and also the patient cohort was in a better 
stage compared to the present study. The difference in survival between those 
starting treatment with cd4 counts of less than 50 cells/cmm and more than 50 
cells/cmm was not significant in this study, indicating the high efficacy of HAART 
in our population. This shows that all cohorts of patients should be treated, even 
though the cohort of patients with very low cd4 counts is usually severely sick. 
This finding has implications in resource poor settings, as until now opportunity of 
getting ART was given to the one with relatively higher cd4 counts whose 
prognosis was considered better than to those with very low cd4 counts. This 
stratification of survival by a cd4 lymphocyte count of 50 cells/cmm was 
motivated by the potential to compare to other studies that have used these 
categories.  
Mortality :  
81.3% of deaths occurred within 3 months of starting therapy, which is similar to 
that in other such studies[37,84] in both developed and developing countries. This 
high rate of death immediately following the start of ART was seen in highly 
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immunocompromised patients with very low cd4 counts, presence of opportunistic 
infections, low BMI, low haemoglobin. Tuberculosis (30.2%), severe wasting with 
chronic diarrhoea(25.5%), pneumocystis jiroveci pneumonia(18.6%) accounted for 
~75% of total deaths similar to other studies in resource poor settings.[39,41,43] Most 
of the deaths occurred in the first three months of start of therapy as was seen in 
other studies.[38-52,] The occurrence of a number of deaths very soon after initiating 
treatment is most likely due to the extreme disease advancement of many patients 
by the time they were able to access treatment.  The relatively short period between 
ART initiation and new OI development suggests that OIs were a result of immune 
reconstitution or, in case of TB, relatively insensitive baseline screening methods. 
Additionally OIs may have developed before the full effects of ART could be 
attained in this immunocompromised population. Innovative approaches are 
required to prevent, diagnose and manage opportunistic infections effectively in 
this population.  
CD4 lymphocyte counts : 
CD4 lymphocyte gains were impressive, a mean gain of 162 cells/cmm at 6 
months and 225 cells/cmm at 12 months from baseline, was  similar to or better 
than a number of studies[37,39,41-44,46,82] in both developed and resource poor 
countries. The cd4 cell gain was almost equal or more  in cohort of patients with 
cd4 count less than 50 cells/cmm than those with more than 50cells/dl. This 
68 
 
finding is  unlike most other studies which showed that cd4 cell gain was less in 
patients with severe immunosupression and similar to study by lawn et al.[91] Those 
with baseline CD4 cell counts <50 cells/µl had a higher rate of cd4 cell gain 
compared to rates among those with higher baseline CD4 cell counts in the first 6 
months after start of ART and had similar gain of cd4 cells in the next 6 months.  
Kaufmann et al. found that CD4 cell increases in the first year of ART were 
similar comparing those with baseline counts <100 cells/µl with those with counts 
100–199 cells/µl. The immunological response to ART among those with low CD4 
cell counts was excellent with the proportion of patients with a CD4 cell count 
<100 cells/µl decreasing from 104 (43%) at baseline to just 7 ( 6%) at 6 months. 
This shows the higher efficacy of HAART in our patient population which is 
reflected by higher immunological recovery.  
Treatment change and toxicity: 
28 patients (11.6%) of a total of 240 started on ART, changed their initial regimen. 
Of them 15 patients (53.5%) changed as they developed new onset TB, 12 patients 
(42.8%) changed their initial regimen as they developed adverse reaction to ART. 
Nevirapine was the drug which caused most adverse effects, mainly skin rash, 
which 6 patients developed, followed by zidovudine.The rates of treatment change 
due to adverse events were uniformly low and lower than those published for other 
cohorts.[37,48,83] This is a reflection of the incidence of severe adverse events in 
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general, and demonstrates that they are very less and with standardized regimens, 
monitoring and clinical management algorithms as in this study, ART can be safely 
used in resource constrained settings. The most common contraindication resulting 
in a treatment change was in patients who developed tuberculosis after starting 
ART and who were switched from nevirapine to efavirenz, due to concerns about 
the co-administration fo nevirapine with rifampicin. 
 Adherence : 
The adherence to ART in this study was >95% for more than 95% of patients of all 
those under follow till the end of study, which is higher than most cohorts in 
western countries and comparable to most other studies in resource poor 
settings.[37-40,41,45,46,54,82]This shows that our patient population take their drugs 
regularly and are more adherent to therapy and also with effective counseling this 
can further be improved. Most common cause for non-adherence was due to 
patients going out of station for work (drivers), followed by forgetfulness.   
  
Some of the studies undertaken in resource poor settings and developed nations are 
summarized in table below, which helps in comparision of our study to other 
similar such studies:  
 
 
70 
 
 
Reference Country, 
year 
Study 
population
Duration 
of 
treatment
CD4 cell 
count/cmm
Mortality Weight 
trend 
kgs 
Toxicity 
event 
[37] Senegal 
2003 
40 ART-
naive 
patients 
15 M Mean↑ 
at15M 
+199  
0% 
 
Mean↑ 
at15M 
5.1±5.3  
 
19 cases 
[39] Malawi 
2004 
141 pts 6 M Median↑ 
6M +92 for 
46 pts 
27% Mean↑ 
at 6M 
+5.7  
4 cases  
[41] Malawi 
2005 
1266 pts 
96.8% 
ART naive 
>6 M NR 12.9% NR NR 
[43] Uganda 
2005 
200 ART-
naive pts 
6 M NR 3% NR NR 
[44] Kenya 
2003 
217 pts 24 M Median↑at 
12M  +74  
11% NR NR 
[46] S.Africa 
2004 
287 ART-
naive pts 
Median, 
13.9 M 
Mean↑ 
+134 6M 
+184 12M  
+220 18M 
+288 24M 
13.7% Mean↑ 
at 12M  
+9  
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[48] Cameroon 
2003 
117 pts 
ART naive 
Median, 
10.5M 
Median↑ 
+250 12M 
7.7% Median 
BMI,  
23  0M 
25 12M 
39 cases 
[50] Nigeria 
2004  
219 pts 12 months Mean↑ 106 
<55yr  
78 >55yr  
 
NR Mean↑ 
+8<55yr  
+5>55yr
 
Seen in 
>55yr 
 
[52] Cote 
d’Ivoire 
2003  
101 pts Median, 
17M 
Median↑ 
+115  12M   
9.9% Mean↑ 
21M 3.4 
  
10 cases 
[60] Botswana 
2004  
146 Pts Median, 
13.5M 
Mean↑  
+249  12M  
Probability  
survival at 
12M    0.7 
 
Mean↑ 
12M  11 
 
NR 
[90] AVANTI 2 
Europe 
Australia 
Canada 
2000 
52 Pts Median, 
52 weeks 
Mean↑  
+178  
52wks 
0% NR 46/52 
(88%) 
 PRESENT  
STUDY 
240 pts Median, 
10M 
Mean↑  
+226  12M 
17.9% Mean↑ 
12M  
4.43 
 
12 cases 
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LIMITATIONS OF THIS STUDY : 
 
There were significant limitations to our study. Because this study was 
observational, not all patients were equal in terms of time in the study, therapy, 
follow up. The period of follow up of patients in this study was 18 months and 
consisted of small number of patients, which could be limitation for identifying 
significant factors for the outcome. The survival analysis and the cox regression 
analysis are time dependent. Since the follow up time was only 18 months, it may 
not support fully to identify the real risk factors. Selection bias was present as 
newly diagnosed adult patients were only considered. The primary data for 
diagnosis and ART management were determined through physician reporting in a 
clinical record; therefore, there were potential inaccuracies or omissions in these 
data. Additionally, no other source of records was used for comparison. 
 
 
 
 
 
 
 
 
 
73 
 
CONCLUSIONS  
 
1. The early clinical outcomes of patients with HIV in our cohort had improved  
on HAART similar to other studies, showing the efficacy of HAART in our 
population. 
2. Clinical outcomes like CD4 count, weight gain, haemoglobin showed a 
significant increase from baseline in our patients on HAART, showing the 
overall improvement of our population with ART.  
3. Adverse events to ART drugs was seen in 5% of patients, which was very 
low compared to other studies, showing that our patients tolerate ART drugs 
well.  
4. 75.6% of opportunistic infections after start of ART were seen within the 
first 4 months; after which their incidence reduced, implying that the full 
effect of antiretroviral drugs starts around this time. 
5. Adherence to ART was more than 95% in more than 95% of patients under 
follow up, which is better than that seen in developed countries, which 
shows that our population is more adherent to therapy. 
74 
 
6. 81.4% of deaths occurred within 3 months of start of therapy in our cohort, 
showing the advanced stage of presentation of these patients to hospital, and 
death before ART could take full effect. 
In conclusion HAART proved to be effective in our cohort of patients and 
our findings support the ongoing feasibility of ART roll out in resource poor 
settings. Widespread voluntary HIV testing and counselling should be 
encouraged to allow HAART initiation before the development of severe 
immune suppression. Free access to HAART, as in this study is also important 
as programmes in which patients had to pay for their treatment have shown 
higher rates of mortality.[75,79] The findings in this study provide encouragement 
to those seeking to provide similar services in resource poor settings where HIV 
morbidity and mortality are high.  
 
 
 
 
 
 
77 
 
 
BIBLIOGRAPHY 
1. Fauci A S, Lane H C. 17th Edition, Harrison’s Principles of Internal 
Medicine. Page 1137-1204. 
2. Heeney, JL, Dalgleish, AG, Weiss, RA. Origins of HIV and the evolution of 
resistance to AIDS. Science 2006; 313:462. 
3. Gao, F, Bailes, E, Robertson, DL, et al. Origin of HIV-1 in the chimpanzee 
Pan troglodytes troglodytes. Nature 1999; 397:436. 
4. Archer, J, Robertson, DL. Understanding the diversification of HIV-1 
groups M and O. AIDS 2007; 21:1693. 
5. Keele, BF, Van Heuverswyn, F, Li, Y, et al. Chimpanzee reservoirs of 
pandemic and nonpandemic HIV-1. Science 2006; 313:523. 
6. Murphey-Corb, M, Martin, LN, Rangan, SR, et al. Isolation of an HTLV-III-
related retrovirus from macaques with simian AIDS and its possible origin in 
asymptomatic mangabeys. Nature 1986; 321:435. 
7. UNAIDS. 2007 AIDS Epidemic Update. Geneva: Joint United Nations 
Program on HIV/AIDS, December 2007. 
78 
 
8. Schwartlander, B, Grubb, I, Perriens, J. The 10-year struggle to provide 
antiretroviral treatment to people with HIV in the developing world. Lancet 
2006; 368:541. 
9. Report on the global AIDS epidemic, 2008. Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 2008. 
10. Steinbrook, R. HIV in India--a complex epidemic. N Engl J Med 2007; 
356:1089.   
11. Gill, B, Okie, S. China and HIV - a window of opportunity. N Engl J Med 
2007; 356:1801. 
12. HIV data from NACO, available at www.naco.org.com 
13. Piot, P. AIDS: from crisis management to sustained strategic response. 
Lancet 2006; 368:526. 
14. Quinn, TC. Global burden of the HIV pandemic. Lancet 1996; 348:99. 
15. Beyrer, C. HIV epidemiology update and transmission factors: risks and risk 
contexts--16th International AIDS Conference epidemiology plenary. Clin 
Infect Dis 2007; 44:981. 
16. Green WC: AIDS and the immune system. Sci Am 1993;269:98 
17. Streicher HZ, Reitz MS, Gallo RC: Human immunodeficiency viruses. 
Principles and practice of Infectious Diseases. Mandell GL, Bennett JE, 
Dolin R, Eds. Churchill Livingstone, Philadelphia, 2000, p 1847 
79 
 
18. Sharp P, Robertson D, Gao F, etal: Origins and diversity of human 
immunodeficiency viruses. AIDS 1994; 265:1193 
19. Mellors JW, Rinaldo CR, Gupta P, et al: prognosis in HIV-1 infection 
predicted by the quantity of virus in plasma. Science 1996; 272:1167 
20. Siliciano JD, Kajdas J, Finzi D, et al: Long-term follow up studies confirm 
thye stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat 
Med 2003; 9:727 
21. Kahn JO, Walker BD: Acute human immunodeficiency virus type 1 
infection. N Engl J Med 1998;339:33 
22. Centers for Disease Control (1993b). 1993 Revised Classification System 
for HIV Infection and Expanded Surveillance Case Definition for AIDS 
Among Adolescents and Adults. MMWR 1992, 41(RR-17). 
http://hiv.net/link.php?id=184 
23. Centers for Disease Control and Prevention. Interpretation and Use of the 
Western-Blot Assay for Serodiagnosis of Human Immunodeficiency Virus 
Type 1 Infections. MMWR 1989;38: 1-7. 
24. http://www.fda.gov/bbs/topics/NEWS/new01726.html 
25. Paul E, John G, Barbara H: Clinical trials of HIV antiretroviral therapy: 
Integrase inhibitors: www. Uptodate.com 
80 
 
26. Adult A. FDA warns of potential protease-inhibitor link ot hyperglycaemia. 
Lancet 1997;349:1819 
27. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity 
induced by nucleoside-analogue reverse-transcriptase inhibitors is a key 
factor5 in the pathjogenesis of antiretroviral-therapy-related lipodystrophy. 
Lancet 1999; 354:1112-5.  
28. http://www.avert.org/ New antiretroviral  drugs 
29. Fischl, MA, Richman, DD, Grieco, MH, et al. The efficacy of 
azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-
related complex. A double-blind, placebo-controlled trial. N Engl J Med 
1987; 317:185. 
30. Early clinical trials of HIV antiretroviral therapy  Sax PE, Bartlett JG, 
McGovern BH, up to date: www. Uptodate.com 
31. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: 
the EuroSIDA study. Lancet 2000, 356:291-6. 
http://amedeo.com/lit.php/id=11071184 
32. Siliciano JD, Kajdas J, Finzi D, et al. long-term follow up studies confirm 
the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Med 
2003;9:727-728. http://amedeo.com/lit.php/id=12754504  
81 
 
33. Outcomes for Patients Receiving Antiretroviral Therapy in the Developing 
World Appear to Be Not Much Different from Those in the Developed 
World, Carlos del Rio and Frances Priddy, Clinical Infectious Diseases 
2005; 41:225–6 
34. Kim  JY, Farmer  P. AIDS in 2006--moving toward one world, one hope?. N 
Engl J Med 2006; 355:645. 
35. Antiretroviral therapy guidelines for HIV infected adults and adolescents 
including postexposure prophylaxis, NACO may 2007 
36. Antiretroviral therapy for HIV infection in adults and adolescents : 
recommendations for a public health approach –2006 rev. WHO 
37. Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active 
antiretroviral therapy in treatment-naive HIV-1–infected adults in Senegal. 
AIDS 2003; 17:1017–22. 
38. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a 
generic fixed-dose combination of nevirapine, stavudine, and lamivudinein 
HIV-1–infected adults in Cameroon: open-label multicentre trial. Lancet 
2004; 364:29–34. 
39. Hosseinipour MC, Kanyama C, Nkhalamba T, et al. Safety and efficacy of 
D4T/3TC/NVP among HIV positive adults in Lilongwe, Malawi [abstract 
82 
 
TuPeB4522]. In: Program and abstracts of the 15th International AIDS 
Conference (Bangkok). Stockholm: International AIDS Society, 2004. 
40. Oyugi JH, Byakika JT, Ragland K, et al. Treatment outcomes and adherence 
to generic Triomune and Maxivir therapy in Kampala, Uganda [abstract 
WeOrB1323]. In: Program and abstracts of the 15th International AIDS 
Conference (Bangkok). Stockholm: International AIDS Society, 2004. 
41. Jeannin A, Pinoges L, Calmy A, et al. Clinical and virological outcomes of 
patients on HAART in a large-scale simplified treatment program in a rural 
district of Malawi [abstract 625]. In: Program and abstracts of the 2nd IAS 
Conference on HIV Pathogenesis and Treatment (Paris) 2003. 
42. Jack C, Lalloo U, Abdool Karim Q, et al. A pilot study of once-daily ART 
integrated with tuberculosis directly observed therapy in a resource-limited 
setting. J Acquir Immune Defic Syndr 2004; 36:929–34. 
43. Mutuluuza CK, Walker S, Kaleebu P, et al. Short-term virologic response to 
a triple nucleoside/nucleotide analogue regimen in adults with HIV infection 
in Africa within the DART Trial [abstract 22]. In: Program and abstracts of 
the 12th Conference on Retroviruses and Opportunistic Infections (Boston). 
Alexandria, VA: Foundation for Retrovirology and Human Health, 2005. 
83 
 
44. Macharia DK, Chang LW, Lule G, et al. Antiretroviral therapy in the private 
sector of Nairobi, Kenya: a review of the experience of five physicians. 
AIDS 2003; 17:938–40. 
45. Laurent C, Fatou Ngom Gueye N, Ndour CT, et al. Long-term benefits of 
highly active antiretroviral therapy in Senegalese HIV-1–infected adults. J 
Acquir Immune Defic Syndr 2005; 38:14–7. 
46. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of 
providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 
18:887–95. 
47. Sow PS, Schillevoort I, Kityo C, et al. Implementing antiretroviral treatment 
in resource-limited settings: clinical results from four African countries 
[abstract ThPeB7158]. In: Program and abstracts of the 15th International 
AIDS Conference. (Bangkok). Stockholm: International AIDS Society, 
2004. 
48. Mougnutou R, Bourgeois A, Nkoue N, Laurent C, Lactouock B, Liege´ois F 
et al. Evaluation of a HAART pilot study in Yaounde, Cameroon: 
HIV/AIDS • CID 2005:41 (1 August) • 385 24 months follow-up [abstract 
686]. In: Program and abstracts of the 2nd IAS Conference on HIV 
Pathogenesis and Treatment (Paris). 2003. 
84 
 
49. Ekong E, Akinlade O, Uwah A, Grant-Isibor I. The Nigerian accelerated 
antiretroviral drug initiative-evaluation of combination of nevirapine (NVP), 
lamivudine (3TC), and stavudine (d4T) in antiretroviral naïve patients 
[abstract 629]. In: Program and abstracts of the 2nd IAS Conference on HIV 
Pathogenesis and Treatment (Paris) 2003. 
50. Ekong E, Akinlade O, Uwah A, Igbu T. Comparative assessment of response 
to HAART of the elderly and young HIV/AIDS patients in a resource-
limited setting [abstract ThPeB7187]. In: Program and abstracts of the 15th 
International AIDS Conference (Bangkok). Stockholm: International AIDS 
Society, 2004. 
51. Idoko JA, Akinsete I, Abalaka AD, et al. A multicentre study to determine 
the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), 
zalcitabine (HIVID) and zidovudine in the treatment of HIV infected 
Nigerian patients. West Afr J Med 2002; 21:83–6. 
52. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, 
morbidity and immunovirological evolution in HIV-infected adults receiving 
antiretroviral therapy, Abidjan, Cote d-Ivoire. Antivir Ther 2003; 8:385–93. 
53. Torpey K, Ampofo W, Nyarko C, Asare R, Antwi P, Essah K. Antiretroviral 
therapy in Ghana: patients’ presentation and response [abstract B10872]. In: 
85 
 
Program and abstracts of the 15th International AIDS Conference 
(Bangkok). Stockholm: International AIDS Society, 2004. 
54. Hudspeth J, Venter W, van Rie A, Wing J, Feldman C. Access to and early 
outcomes of a public South African adult antiretroviral clinic [abstract 625]. 
In: Program and abstracts of the 12th Conference on Retroviruses and 
Opportunistic Infections (Boston). Alexandria, VA: Foundation for 
Retrovirology and Human Health, 2005. 
55. Karcher H, Moses A, Weide AL, Stelzenmueller J, Mayer A, Harms G. 
Evaluation of antiretroviral treatment in Fort Portal, western Uganda 
[abstract B12706]. In: Program and abstracts of the 15th International AIDS 
Conference (Bangkok). Stockholm: International AIDS Society, 2004. 
56. Stringer J, Zulu I, Chi B, et al. Rapid deployment of ART services is feasible 
and effective in resource-limited settings in sub-Saharan Africa [abstract 
638]. In: Program and abstracts of the 12th Conference on Retroviruses and 
Opportunistic Infections (Boston). Alexandria, VA: Foundation for 
Retrovirology and Human Health, 2005. 
57. Kibangou N, Tran-Minh T, Mankou M, et al. Pointe-Noire, Congo- 
Brazzaville: antiretroviral therapy assessment, an evaluation following 6 
months of prescription [abstract 700]. In: Program and abstracts of the 2nd 
IAS Conference on HIV Pathogenesis and Treatment (Paris). 2003. 
86 
 
58. Guiard-Schmid JB, Montagut B, Ribadeau-Dumas F, et al. TRICAM: 
Mmdico-economic pilot study on HAART for HIV-infected patients in a 
private company of Cameroon [abstract MoOrD1024]. In: Program and 
abstracts of the 15th International AIDS Conference (Bangkok). Stockholm: 
International AIDS Society, 2004. 
59. Mujugira A, Wester W, Kim S, et al. Antiretroviral treatment among ARV 
naive HIV-1 subtype C infected adults with CD4 <50 cells/mm3 at treatment 
initiation [abstract TuPeB4529]. In: Program and abstracts of the 15th 
International AIDS Conference (Bangkok). Stockholm: International AIDS 
Society, 2004. 
60. Ndwapi N, Bussman H, Gaolathe T, et al. Response to the Botswana 
national antiretroviral therapy program-preliminary analysis of the first 306 
treatment-nave adults receiving HAART via the national ARV program 
[abstract 1216]. In: Program and abstracts of the 2nd IAS Conference on 
HIV Pathogenesis and Treatment (Paris). 2003. 
61. Emberti Gialloreti L, De Luca A, Perno CF, et al. Increase in survival in 
HIV-1 infected subjects in Matola, Mozambique, after that introduction of 
combination therapy with generic-manufactured antiretrovirals: preliminary 
results from the DREAM cohort [abstract 175]. In: Program and abstracts of 
87 
 
the 10th Conference on Retroviruses and Opportunistic Infections (Boston). 
Alexandria, VA: Foundation for Retrovirology and Human Health, 2003. 
62. . Mascolini M. Trends in antiretroviral tactics. New York: American 
Foundation for AIDS Research, 2002. 
63. Mahajan AP, Hogan JW, Snyder B, et al. Changes in total lymphocyte count 
as a surrogate for changes in CD4 count following initiation of HAART: 
implications for monitoring in resource-limited settings. J Acquir Immune 
Defic Syndr 2004; 36:567–75. 
64. Liechty CA, Bangsberg DR. Doubts about DOT: antiretroviral therapy for 
resource-poor countries. AIDS 2003; 17:1383–7. 
65. Cassol E, Page T, Mosam A, et al. Therapeutic response of HIV-1 subtype C 
in African patients coinfected with either Mycobacterium tuberculosis or 
human herpesvirus–8. J Infect Dis 2005; 191:324–32. 
66. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events 
associated with potent antiretroviral treatment: Swiss HIV Cohort Study. 
Lancet 2001; 358:1322–7. 
88 
 
67. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the 
effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 
infected adults. AIDS 2001; 15:1369–77. 
68. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor 
therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 
133:21–30. 
69. Popp D, Fisher JD. First, do no harm: a call for emphasizing adherence and 
HIV prevention interventions in active antiretroviral therapy programs in the 
developing world. AIDS 2002; 16:676–77. 
70. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of 
antiretroviral-drug–resistant HIV-1 variants. Lancet 1999; 354:729–33. 
71. Akileswaran C, Lurie MN , Timothy P. et al. Lessons Learned from Use of 
Highly ActiveAntiretroviral Therapy in Africa. Clinical Infectious Diseases 
2005; 41:376–85 
72. Staszewski S,Morales-Ramirez J, Tashima KT, et al. Efavirenz plus 
zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus 
zidovudine and lamivudine in the treatment of HIV-1 infection in adults. 
Study 006 Team. N Engl J Med 1999; 341:1865–73. 
89 
 
73. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine 
vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected 
adults: a randomized equivalence trial. JAMA 2001; 285:1155–63. 
74. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus 
nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 
346:2039–46. 
75. Ivers LC, Kendrick D, Doucette K. Efficacy of Antiretroviral Therapy 
Programs in Resource-Poor Settings: A Meta-analysis of the Published 
LiteratureClinical Infectious Diseases 2005; 41:217–24 
76. Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral 
therapy in resource poor settings: the experience of Me´decins Sans 
Frontie`res. 
77. Me´decins Sans Frontie`res. MSF reports on progress and challenges of 
expanding AIDS treatment programs. Bangkok, 2004. Available 
at:http://aids2004.msf.org.hk/en/bbk_aids_pr1 .pdf. 
78. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV 
Observational Database:baseline and retrospective data. J Acquir Immune 
Defic Syndr 2005; 38:174–9. 
79. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. 
Mortality of HIV-1-infected patients in the first year of antiretroviral 
90 
 
therapy: comparison between low income and high-income countries. Lancet 
2006; 367:817–824. 
80. Chan KC, Yip B, Hogg RS, Montaner JS, O’Shaughnessy MV. Survival 
rates after the initiation of antiretroviral therapy strati- fied by CD4 cell 
counts in two cohorts in Canada and the United States. AIDS 2002, 
16:1693–1695. 
81. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as 
predictors of HIV disease progression. Q J Med 1996, 89:505–508. 
82. Smith CJ, Sabin CA, Lampe FC, Kinloch-de-Loes S, Gumley H, Carroll A, 
et al. The potential for CD4 cell increases in HIVpositive individuals who 
control viraemia with highly active antiretroviral therapy. AIDS 2003, 
17:963–969. 
83. d’Arminio MA, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et 
al. Insights into the reasons for discontinuation of the first highly active 
antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive 
patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive 
Patients. AIDS 2000, 14:499–507. 
84. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. 
Assessment of a pilot antiretroviral drug therapy programme in Uganda: 
patients’ response, survival, and drug resistance. Lancet 2002, 360:34–40. 
91 
 
85. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, 
Balakrishnan P, Flanigan TP: Incidence of immune reconstitution syndrome 
in HIV/tuberculosis-coinfected patients after initiation of generic 
antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004, 37:1574-
1576. 
86. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo MD, et al.: 
Determinants of immune reconstitution inflammatory syndrome in HIV type 
1-infected patients with tuberculosis after initiation of antiretroviral therapy. 
Clin Infect Dis 2004, 39:1709-1712. 
87. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling 
TR: Paradoxical worsening of tuberculosis in HIV infected persons. Chest               
2001, 120:193-197. 
88. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White 
AC Jr, Hamill RJ: Incidence and risk factors for immune reconstitution 
inflammatory syndrome during highly active antiretroviral therapy. AIDS 
2005, 19:399-406. 
89. Shao H, Crump J, Ramadhani H, Uiso L, Sendui-Nguyaine , Kiwera R, 
Ndosi1 E, Shao J, Bartlett J, Thielman N: A randomised trial of early versus 
delayed fixed dose combination zidovudine/lamivudine/ abacavir in patients 
coinfected with HIV and tuberculosis: early findings of the tuberculosis and 
92 
 
immune reconstitution syndrome trial. Thirteenth Conference on 
Retroviruses and Opportunistic Infections. Denver, CO, February 2006 . 
[abstract 796]. 
90. The AVANTI study group : Randomized, double-blind trial to evaluate the 
efficacy and safety of zidovudine plus lamivudine versus zidovudine plus 
lamivudine plus indinavir in HIVinfected antiretroviral-naive patients. AIDS 
2000, 14:367-374. 
91. Lawn S D, Myer L, Bekker L, Wood R: CD4 cell count recovery among 
HIV-infected patients with very advanced immunodeficiency commencing 
antiretroviral treatment in sub-Saharan Africa. BMC Infectious Diseases 
2006, 6:59. 
7 
 
                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
3TC   lamivudine                                          
ABC   abacavir 
AFB   acid-fast bacilli 
AIDS   acquired immunodeficiency 
          Syndrome 
 
ALT   alanine aminotransferase 
ART   antiretroviral therapy 
ARV   antiretroviral 
AST   aspartate aminotransferase 
ATV  atazanavir 
AZT   zidovudine (also known as ZDV) 
BMI   body mass index 
CD4   count  CD4+ T-lymphocyte 
CMV   cytomegalovirus 
CTX   co-trimoxazole 
CXR   chest X-ray 
d4T   stavudine 
ddI   didanosine 
 
 
DNA   deoxyribonucleic acid 
DOT   directly observed therapy 
EFV   efavirenz 
EIA   enzyme immunoassay 
EPTB   extrapulmonary tuberculosis 
FBC   full blood count 
FDA   Food and Drug Administration 
(USA) 
FDC   fixed-dose combination 
FPV   fos-amprenavir 
FTC   emtricitabine 
GDG   Guidelines Development Group 
GI   gastrointestinal 
Hb   haemoglobin 
HBV   hepatitis B virus 
HCV   hepatitis C virus 
HDL   high-density lipoprotein 
HIV   human immunodeficiency virus 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OST   opioid substitution treatment 
PCP   Pneumocystis pneumonia 
PGL   persistent generalized 
            lymphadenopathy 
 
PI   protease inhibitor 
PML   progressive multifocal 
            leukoencephalopathy  
 
PMTCT   prevention of mother-to-child 
                transmission (of HIV) 
 
/r low-dose   ritonavir 
RBV    ribavirin 
RNA   ribonucleic acid 
RT   reverse transcriptase 
RTI   reverse transcriptase inhibitor 
RTV   ritonavir 
SJS   Stevens-Johnson syndrome 
SQV   saquinavir 
STI   sexually transmitted infection 
 
 
HSV   herpes simplex virus 
IDU   injecting drug user 
IDV   indinavir 
INH   isoniazid 
IRIS   immune reconstitution 
           inflammatory syndrome 
 
LDH   lactic dehydrogenase 
LPV   lopinavir 
MTCT   mother-to-child transmission (of 
HIV) 
NAM   nucleoside/nucleotide analogue 
            Mutation 
 
NFV   nelfinavir 
NNRTI   non-nucleoside reverse 
                 transcriptase inhibitor 
 
NRTI   nucleoside reverse transcriptase 
              inhibitor 
 
NVP   nevirapine 
OHL   oral hairy leukoplakia 
OI   opportunistic infection 
 
 
9 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TB   tuberculosis 
TDF   tenofovir disoproxil fumarate 
TENS   toxic epidermal necrolysis 
TLC   total lymphocyte count 
VL   viral load 
UNAIDS   Joint United Nations      
                  Programme on  
                  HIV/AIDS 
 
USA United States of America    
 WBC   white blood cell count 
WHO   World Health Organization 
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      HAART OUTCOMES IN  HIV :   PROFORMA 
 
Name:  
Age:  
Sex: 
Education : 
Occupation: 
Married Y/N: 
Hiv status :  Date of initial detection, 
   CDC stage,  
Status of spouse 
Route of acquisition: heterosexual, homosexual, iv drug use, blood transfusion 
H/O opportunistic infections: past and present 
Co morbidities: Diabetes, hypertension, congestive heart failure, hepatitis B/C  
H/O Smoking,  alcoholism  
Drugs on use:   ART, ATT, antibiotics – cotrimoxazole, quinolones, fluconazole 
For pt newly started on ART: Regimen 
For pt on follow up : new complaints, new OI, adherence to drugs 
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 EXAMINATION 
   Height                           weight                                           BMI         
   Pulse                             BP (upper limb) 
   CVS                RS                    Abd                                       CNS 
 
INVESTIGATIONS :  
CBC: Hb, TC, DC, ESR, PCV, PLTS 
Renal Function Test: sugar, urea, creatinine, Na, K 
Liver function tests: 
CD4 COUNT 
Sputum examination for TB bacilli : if indicated  
CXR: if indicated 
USG abdomen: if indicated 
Date Weight CD4 count HB OI Adherence 
0 M      
6 M      
12 M      
18 M      
